A clinical case of liver fibrosis in type 1 diabetes mellitus
https://doi.org/10.31146/1682-8658-ecg-240-8-195-198
Abstract
Glycogenic hepatopathy is a rare and often underdiagnosed condition predominantly associated with type 1 diabetes mellitus. This article presents a clinical case of a female patient with liver fibrosis in the context of uncontrolled type 1 diabetes. Examination revealed hyperglycemia, elevated HbA1c (7.28%), and persistently increased transaminase levels (ALT up to 248.9 U/L, AST up to 155.0 U/L). Fibroelastometry and liver biopsy confirmed fibrosis (F0-F4 according to the METAVIR score) and minimally active steatohepatitis. The role of glucose and glycogen metabolism disorders in the development of glycogenic hepatopathy and fibrosis is discussed. Following the optimization of insulin therapy, a decrease in both fibrosis and transaminase levels was observed. Maintaining target HbA1c levels, adhering to dietary recommendations, and regular monitoring of liver function are recommended to prevent disease progression.
About the Authors
A. V. Vlasov
Saratov City Polyclinic No. 20"; State budgetary institution of health care of the Moscow region "Domodedovo hospital"
Russian Federation
Russian Federation
A. V. Oskina
Saratov City Polyclinic No. 20"; State budgetary institution of health care of the Moscow region "Domodedovo hospital"
Russian Federation
Russian Federation
A. M. Kanaev
Saratov City Polyclinic No. 20"; State budgetary institution of health care of the Moscow region "Domodedovo hospital"
Russian Federation
Russian Federation
References
1. Sundaram S, Alkhouri N, Cikach F. et al. Glycogenic Hepatopathy in Type 1 Diabetes: An Underrecognized Complication. Diabetes Care. 2013;36(1): e6-e6. doi: 10.2337/dc12-1568.
2. American Diabetes Association. Standards of Medical Care in Diabetes-2023. Diabetes Care, 2023; 46(Suppl.1): S1-S274. doi: 10.2337/dc23-S002.
3. Cusi K., Chang Z. L., Harrison S. et al. Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening. Diabetes Care, 2021; 44(2): 399-407. doi: 10.2337/dc20-199.
4. Moore M. C., Coate K. C., Winnick J. J., An Z., Cherrington A. D. Regulation of hepatic glucose uptake and storage in vivo. Advances in Nutrition. 2012 May 1;3(3):286-94. doi: 10.3945/an.112.002089.
5. Wan Y., Hu Z., Liu Q. et al. Liver fibrosis alters the molecular structures of hepatic glycogen. Carbohydrate Polymers. 2022 Feb 15;278:118991. doi: 10.1016/j.carbpol.2021.
6. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Journal of Hepatology. 2016; 64:1388-1402. doi: 10.1016/j.jhep.2015.11.004.
7. Chalasani N., Younossi Z., Lavine J. E. et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018; 67(1): 328-357. doi: 10.1002/hep.29367.
Review
For citations:
Vlasov A.V., Oskina A.V., Kanaev A.M. A clinical case of liver fibrosis in type 1 diabetes mellitus. Experimental and Clinical Gastroenterology. 2025;(8):195-198. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-240-8-195-198
Views:
10
JATS XML
Email this article 
